globenewswire

Lægemiddelstyrelsen har netop godkendt Itulazax, den første tabletbaserede allergivaccination til behandling af børn og unge i alderen fem til 17 år med træpollenallergi i Danmark.

Aix-en-Provence, 17 June 2025 (8.00 a.m.)

Leading European intellectual property law firm implements IP management platform featuring autonomous time capture and billing

Press release
Telstra and Nokia partner to unlock network APIs for developers and enterprises

Aix-en-Provence, le 17 juin 2025 (8h)

“Peace Artist” Recognised for Lifelong Contribution to Art and Humanity

New Taipei City, Taiwan, June 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (the “Company”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced the pricing of its initial public offering (the “Offering”) of 2,666,667 ordinary shares (the “Ordinary Shares”) at a public offering price of $7.50 per share. The Company expects to receive aggregate gross proceeds of approximately $20 million, before deducting underwriting discounts and other offering expenses. The Ordinary Shares have been approved for listing on the Nasdaq Global Market and are expected to commence trading on June 17, 2025 under the ticker symbol “MENS”. The Offering is expected to close on June 18, 2025, subject to the satisfaction of customary closing conditions. In addition, the Company has granted the underwriters an option (the "Over-Allotment Option"), within 45 days from the date of the final prospectus, to purchase up to an additional 400,000 Ordinary Shares at the public offering price, less underwriting discounts, to cover the Over-Allotment Option, if any.

Monterey, CA, June 16, 2025 (GLOBE NEWSWIRE) -- ChampionsGate Acquisition Corporation (the “Company”) (Nasdaq: CHPGU), a blank check company, today announced that, commencing on June 20, 2025, holders of the 7,475,000 units (the “Units”) sold in the Company’s initial public offering (the “Offering”) including Units sold upon a full exercise of the underwriters’ over-allotment option, may elect to separately trade the Class A ordinary shares and rights included in the Units. Any Units not separated will continue to trade on the NASDAQ Global Market (“NASDAQ”) under the symbol “CHPGU.” Any underlying Class A ordinary shares and rights that are separated will trade on the NASDAQ under the symbols “CHPG” and “CHPGR,” respectively. Holders of Units will need to have their brokers contact the Company’s transfer agent, Continental Stock Transfer & Trust Company, in order to separate the holders’ Units into Class A ordinary shares and rights.

QUEBEC CITY, Canada, June 16, 2025 (GLOBE NEWSWIRE) -- LeddarTech^® Holdings Inc. (“LeddarTech” or the “Company”) (Nasdaq: LDTC), an AI-powered software company recognized for its innovation in advanced driver assistance systems (ADAS) and autonomous driving (AD), today announces that, further to its press release dated June 11, 2025, it intends on making an assignment into bankruptcy pursuant to the Bankruptcy and Insolvency Act (Canada) (the “BIA”).

QUÉBEC, Canada, 16 juin 2025 (GLOBE NEWSWIRE) -- LeddarTech^® Holdings Inc. (« LeddarTech » ou la « Société ») (NASDAQ : LDTC), une société de logiciels reposant sur l’IA reconnue pour son innovation dans les systèmes avancés d’aide à la conduite (systèmes ADAS) et de conduite autonome (systèmes AD), annonce aujourd’hui qu’à la suite de son communiqué du 11 juin 2025, elle a l’intention de faire une cession de faillite en vertu de la Loi sur la faillite et l’insolvabilité (la « LFI »).

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Hallador Energy Company (“Hallador” or the “Company”) (NASDAQ:HNRG)on behalf of Hallador stockholders. Our investigation concerns whether Hallador has violated the federal securities laws and/or engaged in other unlawful business practices.

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Reckitt Benckiser Group plc (OTC:RBGLY), UroGen Pharma Ltd. (NASDAQ:URGN), Red Cat Holdings, Inc. (NASDAQ: RCAT) and Fortrea Holdings Inc. (NASDAQ:FTRE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.